OnDemand Glaucoma Update 2025: Point and Counterpoint, Novel and Interdisciplinary Glaucoma Management Considerations

We will discuss the latest advances in the management of glaucoma and evidence for emerging therapies and screening modalities. Both point/counter-point and didactic formats will be utilized to illustrate current trends in the management of complex and routine glaucoma patients, taking into account novel techniques as well as interdisciplinary glaucoma management.

1. Appropriately refer glaucoma patients in need of advanced treatment
2. Manage or refer patients with complex ocular pathology
3. Order and interpret glaucoma diagnostic tests
4. Evaluate and implement when appropriate new glaucoma surgical procedures
5. Improve practitioner self-care

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 3.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Jason Flamendorf, MD
Society Hill Ophthalmic Associates

Faculty

Nothing to disclose

Lauren Hock, MD
Wills Eye Hospital

Faculty

Grant or research support-National Eye Institute

Ping Huang, MD, PhD
Wills Eye

Faculty

Nothing to disclose

Lindsay Machen, MD
Wills Eye Hospital

Faculty

Other: Investor-Elios Vision (Relationship has ended)

Danijel J Pericic, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Reza Razeghinejad, MD
WEH

Faculty

Grant or research support-Olleyes|Grant or research support-Equinox (Relationship has ended)

Jesse Richman, MD
Kremer Eye Center

Faculty

Consulting Fee-Alcon|Royalties or Patent Beneficiary-Visionology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Visionology (Relationship has ended)|Paid consultant-Allergan (Relationship has ended)

Marisa Schoen, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Joel S Schuman , MD
Wills Eye Hospital

Faculty

Consulting Fee-Zeiss|Advisor-Opticient|Private Corp Stock-Opticient|Advisor-AEYE Health|Private Corp Stock-AEYE Health|Consulting Fee-Alcon|Consulting Fee-Broadwing|Private Corp Stock-Ocugenix|Advisor-Ocugenix|Consulting Fee-Perfuse|Grant or research support-Perfuse (Relationship has ended)|Consulting Fee-Ocular Therpeutics|Public Corp Stock-Ocular Therapeutix|Consulting Fee-Dompé |Grant or research support-Topcon

Meera Sivalingam, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Alice Williams, MD
Friedberg Eye Associates

Faculty

Nothing to disclose

Tina Xia, MD
Wills Eye

Faculty

Grant or research support-AbbVie

Cindy Zheng , MD
Eye Physicians

Faculty

Nothing to disclose

Dilru C Amarasekera, MD
Wills Eye Hospital

Faculty, Planner

Nothing to disclose

Michael Pro, MD
Ophthalmic Partners of PA

Faculty, Planner

Consulting Fee-Alcon|Consulting Fee-New World Medical

Ralph C. Eagle Jr., MD
Director
Wills Eye Hospital

Other Planning Committee Member

Stocks or stock options, excluding diversified mutual funds-Merck